Choice Equity Broking has issued a buy call for Glenmark Pharmaceuticals, setting a target price of Rs 1,779. The brokerage projects robust growth for the pharmaceutical company, fueled by new product launches and expanding margins. They anticipate a 14.8% revenue CAGR and a 44.7% EBITDA CAGR from FY24-27E. Glenmark recently reported a consolidated total income of Rs 3473.
| Subscribe To Our Free Newsletter |
